

Abstract:

The development of new therapies for cancer has dramatically changed the landscape of treatment and survival for several malignancies. These advances, however, have come at the cost of adverse effects, including cardiovascular side effects, which can generate acute and/or chronic morbidity and mortality, interfering with the continuation and benefit of best-possible cancer care. Importantly and to a degree paradoxically, with the introduction of newer targeted cancer therapies, the incidence, spectrum, and severity of cardiovascular toxicities has increased. Cardiac toxicity including myocarditis, vascular toxicities such as myocardial infarction and stroke, and arrhythmias and QTc prolongation are the leading life-threatening cardiovascular side effects of cancer therapies that every practitioner should be familiar with. This presentation will summarize the related latest developments at the juncture of cardiology, oncology and hematology, i.e. cardio-oncology, including key points from the 2022 guidelines of the European Society of Cardiology on Cardio-Oncology and initiatives of the International Society of Cardiology. The narrative will be placed in the context of developing world-wide trends and conclude on the uniqueness of Asian countries such as Korea.